As reported in the Journal of Clinical Oncology by Julie R. Brahmer, MD, of the Johns Hopkins Kimmel Cancer Center, and colleagues, ASCO has released a clinical practice guideline on management of immune-related adverse events in patients receiving immune checkpoint inhibitor therapy. To develop the guideline, ASCO brought together a multidisciplinary, multiorganizational panel of experts in medical oncology, dermatology, gastroenterology, rheumatology, pulmonology, endocrinology, urology, neurology, hematology, emergency medicine, nursing, clinical trials, and advocacy. The expert panel was co-chaired by Dr. Brahmer and John A. Thompson, MD, of the Seattle Cancer Care Alliance, the University of Washington, and Fred Hutchinson Cancer Research Center.
A systematic review of publications from 2000–2017 identified 204 relevant publications, with much of the evidence consisting of systematic reviews of observational data, consensus guidelines, case series, and case reports. As stated by the authors, due to the paucity of high-quality evidence on management of immune-related adverse events, recommendations are based on expert consensus.
The following summarizes/reproduces general recommendations to be followed irrespective of affected organs. The guideline provides detailed recommendations for organ-specific management—ie, skin, gastrointestinal, lung, endocrine, musculoskeletal, renal, nervous system, hematologic, cardiovascular, and ocular immune-related adverse events. All recommendations in the guideline are based on expert consensus, benefits outweigh harms, and moderate strength of recommendation.
The corresponding author of the Journal of Clinical Oncology article is ASCO.
The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.